Advancing COPD Drug Development Through Biomarker-Driven, Clinically Meaningful Innovation
COPD drug development is entering a critical phase, marked by the emergence of first-in-class biologics, a growing pipeline targeting inflammatory and regenerative pathways, and a shift toward precision medicine and disease modification.
Built for pharma and biotech drug developers, this summit brings together senior leaders advancing COPD assets to tackle the key scientific and clinical challenges that limit success. Unlike broader respiratory or academic meetings, it is focused on real-world pipeline progression, enabling open discussion and practical problem-solving among decision-makers.
- Join 60+ senior leaders from pharma and biotech organizations shaping the next generation of COPD therapies and accelerating pipeline progress
- Forge valuable relationships with experts, overcoming shared scientific, clinical, and regulatory hurdles
- Leave with practical strategies to accelerate development timelines and maximize the success of your COPD pipeline
Why COPD Drug Development Needs a New Approach
COPD Trials Rely on Endpoints That Don’t Show True Clinical Value
Endpoints such as exacerbation rates and FEV₁ often fail to capture early disease modification or meaningful patient benefit, limiting differentiation and regulatory confidence
Heterogenous Patient Populations Lead to Challenging Trial Design
Clinical heterogeneity across eosinophilic, neutrophilic, and mixed endotypes dilutes treatment effects and complicates trial design
Preclinical Models Don’t Predict What Happens in the Clinic
Traditional preclinical models struggle to predict human disease, contributing to high late-stage attrition
We Lack Objective Tools to Detect Progression and Prove Early Benefit
A lack of validated biomarkers and sensitive imaging tools delays early proof-of-concept and increases development risk
★ Featured Session: A Patient-Inspired Future for COPD Drug Development
From COPD Foundation
Exclusively At The COPD Drug Development Summit
Gain a direct understanding of how patients experience disease progression, exacerbations, and treatment response beyond traditional endpoints. This session will explore how incorporating patient-reported outcomes and lived experience can strengthen endpoint selection, improve trial relevance, and support more compelling regulatory and commercial narratives.
Explore the Full Event Guide
- Network with 65+ discovery, translational, clinical and regulatory experts from the likes of Johnson & Johnson, Sanofi, GSK, AstraZeneca, Merck, Connect Biopharma, Generate Biomedicines, Ethris, and many more
- Critical debates on regulatory expectations and opportunities to validate novel endpoints that de‑risk development and support faster, more confident approvals
- Expert perspectives on combining imaging, molecular, and clinical data to build a more holistic view of COPD biology and improve translational success
- Hear from 16+ respiratory specialists and C-level executives presenting novel targets and clinical trial strategies
- 3 days of essential industry collaboration including over 6 hours of specialized networking
Attending Companies Include
Explore the Brand-New Agenda
Gain direct insight into how leading pharma and biotech teams are advancing COPD pipelines, with case studies and discussions focused on biomarker-led trials, emerging biologics, and strategies to overcome translational and regulatory barriers.
Partner With Us
Position your organisation alongside leading solution providers and engage directly with pharma and biotech teams actively advancing COPD pipelines, looking for partners to accelerate development.
Join a Highly Curated Respiratory Community
Build meaningful connections with the people shaping next-generation COPD